Scientists recently identified the structure of the cannabinoid-1 receptor, which is the receptor of the endocannabinoid system responsible for binding with THC. The CB1 receptor is classified as a GPCR protein, which is the most common class of receptor proteins in our body and of which 40% of drugs are developed to target. Technological advancements in X-Ray crystallography have allowed scientists to develop CB1 crystals. With this new information, scientists will be able to understand how THC binding affects the protein differently from other binding partners, and how the receptor functions at an atomic scale so that they can better understand its role in the treatment of diseases like epilepsy and obesity.
This information has been provided by High Times Magazine and approved by our Chief Medical Officer.